Ipilimumab
Skin Basal Cell Carcinoma
National Cancer Institute (NCI)monoclonal_antibodyPhase 1/2Active
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 40/ 100
- Competitive Position
- 89/ 100
Competitive context
10 Active assets in the Skin Basal Cell Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nivolumab Fred Hutchinson Cancer Center | Phase 2 | B |
Liposomal T4N5 Lotion National Cancer Institute (NCI) | Phase 2 | B |
L19IL2/L19TNF Philogen S.p.A. | Phase 2 | CCC |
Patidegib Sol-Gel Technologies, Ltd. | Phase 2 | CCC |
Prednisone National Cancer Institute (NCI) | Phase 1/2 | CCC |
View all 20 →
Same molecule, other indications
Ipilimumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →